We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Oncodesign and Ipsen Enter Into a Research Collaboration

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Oncodesign and Ipsen Enter Into a Research Collaboration"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Oncodesign and Ipsen have announced that the two companies have entered into a research collaboration to discover and develop innovative LRRK2 kinase inhibitors as potential therapeutic agents against Parkinson's Disease and for potential additional uses in other therapeutic areas.

Oncodesign and Ipsen will leverage their respective expertise to bring innovative therapeutic solutions to Parkinson patients.

Oncodesign’s Nanocyclix® is a proprietary medicinal chemistry technology based on a macrocyclisation process of small chemical molecules that gives access to potent and highly selective small molecule kinase inhibitors with attractive physicochemical and ADME properties.

Oncodesign has identified Nanocyclix® leads against a broad range of known and unexplored kinases (notably the LRRK2 program) with potential in multiple therapeutic areas.

Ipsen will apply its expertise in pharmaceutical R&D and translational sciences while leveraging its network of academic and medical leaders in neurosciences.

“We are very proud and excited to have been selected by Ipsen as a partner on this innovative research collaboration. This agreement advances our strategy to partner on Drug Discovery activities in addition to our well known preclinical evaluation Service Activities in advanced Oncology pharmacology", said Philippe Genne, Ph.D., Chief Executive Officer and founder of Oncodesign.

Jan Hoflack, Ph.D., Chief Scientific Officer and Leader of Oncodesign's Discovery Activities added: "This Agreement allows us to advance our series of attractive LRRK2 inhibitors together with a partner with recognized expertise in CNS Research. This is our first Drug Discovery partnership with a major biopharmaceutical company based on our Nanocyclix® technology, validating our ability to identify uniquely potent and selective novel kinase inhibitors for use in Oncology, CNS and other Therapeutic areas."

Claude Bertrand, Ipsen’s Executive Vice President, R&D and Chief Scientific Officer, stated: “Our collaboration with Oncodesign is the expression of our recently announced strategy to extend our R&D through expert external partners for compounds outside our chosen areas of focus, peptides and toxins. In the field of Neurology and Movement Disorders, Parkinson’s disease is a serious condition with high unmet medical needs where patients are seeking improved care and quality of life. Today, there is no treatment targeting the underlying pathogenetic mechanism leading to progressive deterioration in those patients.”